Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. [electronic resource]
Producer: 20171024Description: 3462-3471 p. digitalISSN:- 1558-8238
- Adult
- Antineoplastic Agents -- chemistry
- Brentuximab Vedotin
- CD28 Antigens -- chemistry
- Disease Progression
- Dose-Response Relationship, Drug
- Female
- Hodgkin Disease -- immunology
- Humans
- Immunoconjugates -- administration & dosage
- Immunophenotyping
- Ki-1 Antigen -- metabolism
- Lymphoma, Large-Cell, Anaplastic -- immunology
- Male
- Middle Aged
- Molecular Targeted Therapy
- Neoplasm Recurrence, Local
- Receptors, Antigen, T-Cell -- chemistry
- T-Lymphocytes -- cytology
- Transplantation Conditioning
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article
There are no comments on this title.
Log in to your account to post a comment.